7.99
+0.01(+0.13%)
Currency In USD
| Previous Close | 7.98 |
| Open | 7.99 |
| Day High | 8 |
| Day Low | 7.98 |
| 52-Week High | 8 |
| 52-Week Low | 1.31 |
| Volume | 418,215 |
| Average Volume | 1.36M |
| Market Cap | 372.91M |
| PE | -3.88 |
| EPS | -2.06 |
| Moving Average 50 Days | 5.43 |
| Moving Average 200 Days | 3.29 |
| Change | 0.01 |
If you invested $1000 in Vigil Neuroscience, Inc. (VIGL) since IPO date, it would be worth $631.62 as of July 04, 2025 at a share price of $7.99. Whereas If you bought $1000 worth of Vigil Neuroscience, Inc. (VIGL) shares 2 years ago, it would be worth $817.81 as of July 04, 2025 at a share price of $7.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
GlobeNewswire Inc.
Jun 04, 2025 11:00 AM GMT
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an u
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
GlobeNewswire Inc.
May 21, 2025 11:30 PM GMT
- Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition exp
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer’s disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLO